⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 3, 2024Expert Opinion on Biological Therapy

Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients

Jaromir Tomasik Dominik Bilicki Grzegorz Basak

View at Publisher

Ask AI

Bookmark

Share

Abstract

Introduction The prognosis for large B-cell lymphoma (LBCL) patients who did not respond or relapsed after chimeric antigen receptor (CAR)-T therapy remains dismal, with no established consensus on the most effective salvage regimen.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tomasik et al. (2024) studied this question.

synapsesocial.com/papers/68e6ba77b6db64358763b835 https://doi.org/10.1080/14712598.2024.2354371

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Association of high-grade biology with marked salvage refractoriness following CD19 CAR T-cell therapy failure in large B-cell lymphoma: A systematic review and meta-analysis.Human Clinical Trial · 2026
2A focus on LBCL patients in partial remission in the CAR-T era2025
3Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA groupCohort Study · 2026
4First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy2025
5CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.Human Clinical Trial · 2026

More related papers

A multicenter retrospective study of HDAC inhibitor- based regimen for relapsed/refractory non-hodgkin lymphoma patients post CAR-T therapy2025
Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy2024
Efficacy and safety analysis of CAR-T cell salvage therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment2026

More from Expert Opinion on Biological Therapy

Current and emerging sublingual immunotherapies for dust mite allergyTue,
An evaluation of sacituzumab tirumotecan for the treatment of NSCLCFri,